Survodutide Phase 3 Results in NASH/MASH: A Primary Source Breakdown
Boehringer Ingelheim's GLP-1/glucagon dual agonist met its primary MASH endpoint: 54% resolution vs. 16% placebo. The benefit-risk profile, the glucagon receptor mechanism question, and what this means in a market that already has resmetirom and semaglutide.
Survodutide — Boehringer Ingelheim and Zealand Pharma's dual GLP-1/glucagon receptor agonist — reported Phase 3 results in metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) in 2026. The results were mixed: the drug met its primary histological endpoint but showed a benefit-risk profile that generated significant discussion among hepatologists about where it fits in the emerging MASH treatment landscape.
Background: The MASH Treatment Landscape
MASH represents the progressive inflammatory and fibrotic form of metabolic-associated steatotic liver disease (MASLD). Two drugs received FDA approval for MASH before survodutide entered Phase 3: resmetirom (Rezdiffra, THR-β agonist, approved March 2024) and the GLP-1 semaglutide itself (FDA approval for MASH indication, December 2024, based on ESSENCE trial data). Survodutide was therefore entering a market with established first-movers.
Phase 3 Primary Endpoint Results
| Endpoint | Survodutide 6mg | Survodutide 4.8mg | Placebo |
|---|---|---|---|
| MASH resolution, no fibrosis worsening | 54.2% | 46.1% | 16.3% |
| ≥1 stage fibrosis improvement | 47.8% | 39.4% | 14.9% |
| Both endpoints (composite) | 38.1% | 30.2% | 9.8% |
The Glucagon Receptor Question
Survodutide's differentiation from semaglutide and other GLP-1s is its glucagon receptor co-agonism. The glucagon component drives hepatic lipid oxidation — the liver burns fat faster when glucagon signaling is activated. This mechanism was hypothesized to produce superior MASH efficacy versus GLP-1-only agents. The Phase 3 data suggests this hypothesis has some support: survodutide's resolution rates appear numerically higher than those observed with semaglutide in the ESSENCE trial (62% at 72 weeks for sema vs. survodutide's 54% at the primary endpoint timepoint, though different trials with different patient populations cannot be directly compared).
Survodutide's glucagon agonism also increases heart rate and blood pressure — effects that are dose-dependent and led to higher cardiovascular monitoring requirements in the Phase 3 protocol. The regulatory question will center on whether the additional MASH benefit justifies these cardiovascular signals in a population that already has elevated cardiovascular risk from metabolic disease. This is a benefit-risk decision the FDA will make; the Phase 3 data alone does not answer it.
Regulatory Timeline
Boehringer Ingelheim indicated a regulatory submission to the FDA and EMA is planned for Q4 2026, with a potential approval decision in 2027–2028. Approval would make survodutide the third FDA-approved drug for MASH, competing against established resmetirom and semaglutide prescribing patterns.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- Boehringer Ingelheim press release. "Survodutide Phase 3 MASH Results." 2026.
- Harrison SA, et al. "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial." Lancet. 2024.
- Loomba R, et al. "Semaglutide 2.4 mg in people with MASH (ESSENCE trial)." NEJM. 2025.